Acquired BCL2 Variants Associated with Venetoclax Resistance in Acute Myeloid Leukemia

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Oct 7

PMID 39374584

Authors

Fiona C Brown

Xin Wang

Richard Birkinshaw

Chong Chyn Chua

Thomas Morley

Sila Kasapgil

Giovanna Pomilio

Piers Blombery

David C S Huang

Peter Czabotar

Salvatore F Priore

Guang Yang

Martin Carroll

Andrew H Wei

Alexander E Perl

Affiliations

Soon will be listed here.

Citing Articles

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.

Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N Curr Oncol. 2024; 31(11):6632-6658.

PMID: 39590121 PMC: 11592437. DOI: 10.3390/curroncol31110490.

References

Nechiporuk T, Kurtz S, Nikolova O, Liu T, Jones C, DAlessandro A . The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925. PMC: 6606338. DOI: 10.1158/2159-8290.CD-19-0125. View

Bhatt S, Pioso M, Olesinski E, Yilma B, Ryan J, Mashaka T . Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020; 38(6):872-890.e6. PMC: 7988687. DOI: 10.1016/j.ccell.2020.10.010. View

Thijssen R, Diepstraten S, Moujalled D, Chew E, Flensburg C, Shi M . Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021; 137(20):2721-2735. PMC: 8138548. DOI: 10.1182/blood.2020010167. View

Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H . Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022; 7(1):51. PMC: 8858957. DOI: 10.1038/s41392-021-00870-3. View

Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L . Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia. Haematologica. 2019; 104(9):e434-e437. PMC: 6717583. DOI: 10.3324/haematol.2019.222588. View

Blombery P, Thompson E, Nguyen T, Birkinshaw R, Gong J, Chen X . Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020; 135(10):773-777. PMC: 7146015. DOI: 10.1182/blood.2019004205. View

Blombery P, Anderson M, Gong J, Thijssen R, Birkinshaw R, Thompson E . Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov. 2018; 9(3):342-353. DOI: 10.1158/2159-8290.CD-18-1119. View

Landsburg D, Morrissette J, Nasta S, Barta S, Schuster S, Svoboda J . TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era. Blood Adv. 2023; 7(23):7243-7253. PMC: 10698538. DOI: 10.1182/bloodadvances.2023011384. View

Chyla B, Daver N, Doyle K, McKeegan E, Huang X, Ruvolo V . Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia. Am J Hematol. 2018; . PMC: 6120451. DOI: 10.1002/ajh.25146. View

10.

Agarwal S, DiNardo C, Potluri J, Dunbar M, Kantarjian H, Humerickhouse R . Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clin Ther. 2017; 39(2):359-367. DOI: 10.1016/j.clinthera.2017.01.003. View

11.

Pei S, Pollyea D, Gustafson A, Stevens B, Minhajuddin M, Fu R . Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020; 10(4):536-551. PMC: 7124979. DOI: 10.1158/2159-8290.CD-19-0710. View

12.

DiNardo C, Tiong I, Quaglieri A, MacRaild S, Loghavi S, Brown F . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803. PMC: 7068032. DOI: 10.1182/blood.2019003988. View

13.

Blombery P, Birkinshaw R, Nguyen T, Gong J, Thompson E, Xu Z . Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. Br J Haematol. 2019; 186(6):e188-e191. DOI: 10.1111/bjh.16069. View

14.

Birkinshaw R, Gong J, Luo C, Lio D, White C, Anderson M . Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun. 2019; 10(1):2385. PMC: 6547681. DOI: 10.1038/s41467-019-10363-1. View

15.

Fresquet V, Rieger M, Carolis C, Garcia-Barchino M, Martinez-Climent J . Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014; 123(26):4111-9. DOI: 10.1182/blood-2014-03-560284. View

16.

Moujalled D, Brown F, Chua C, Dengler M, Pomilio G, Anstee N . Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood. 2022; 141(6):634-644. PMC: 10651776. DOI: 10.1182/blood.2022016090. View